Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
US ophthalmic drugmaker ISTA Pharmaceuticals (Nasdaq: ISTA), which rejected a hostile takeover bid from Canadian firm Valeant Pharmaceuticals (The Pharma Letter January 31), has succumbed to an offer of $500 million - or $9.10 per share -from eye care giant Bausch & Lomb (NYSE: BOL). The transaction, which has been unanimously approved by the boards of directors of both companies, is expected to close in the second quarter of 2012. 27 March 2012
Pharmaceutical
In its third takeover announcement this year, Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an agreement to acquire Natur Produkt International, a specialty pharmaceutical company based in Russia. 27 March 2012
Pharmaceutical
Confirming its previous announcements on plans to split the US health care major, Abbott Laboratories (NYSE: ABT) says that AbbVie will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of this year. 22 March 2012
Pharmaceutical
UK-based Synergy Health (LSE: SYR), a provider of outsourced sterilization services to the medical device market and health care sector, has acquired Leoni Studer Hard from Leoni Group for a cash consideration of 47.6 million euros ($62.7 million), which will be funded out of existing debt facilities. 19 March 2012
Pharmaceutical
French drug major Sanofi (Euronext: SAN) said on Friday that it is to acquire Pluromed, a USA-based medical device company. The transaction, financial terms of which were not disclosed, is subject to customary closing conditions. 18 March 2012
Pharmaceutical
Ireland-headquartered Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire privately-held US firm FerroKin BioSciences for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets. 16 March 2012
Pharmaceutical
Following its earlier announcement that it intends to divest non-core Consumer Healthcare over-the-counter (OTC) products mainly in the USA and Europe with aggregate sales of approximately £500 million ($785 million), UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has reached agreement to divest the previously identified brands in Europe to Belgium-based Omega Pharma (OME: BB) for £470 million euros ($616.6 million) in cash. 15 March 2012
Pharmaceutical
Ireland-based Elan Corp (NYSE: ELN) revealed yesterday that it has raised around $381 million in net proceeds from the sale of 76% (24.15 million ordinary shares) of its 18% shareholding in US drugmaker Alkermes (Nasdaq: ALKS), net of underwriter fees. These proceeds further strengthen the cash balances and capital structure of Elan, the company said. 14 March 2012
Pharmaceutical
US OTC and household products company Prestige Brands Holdings (NYSE: PBH) has turned down an $834 million - or $16.60 per share - bid by Mexican drugmaker Genomma Lab Internacional, saying it is inadequate and not in the best interest of the company or its shareholders. 14 March 2012
Pharmaceutical
Speaking at the companys annual meeting, Swiss drug maj'or Roche (ROG: SIX) chairman Franz Humer said: "Our strategy of concentrating on pharmaceuticals and diagnostics and our sharp focus on innovation will also be key for our future success. The proposed acquisition of Illumina would strengthen our Diagnostics Division because gene sequencing will be a key technology going forward. Roche and Illumina would benefit from a rapid merger. However, this is an area where we have other options should the transaction fail over price." 7 March 2012
Pharmaceutical
In a second acquisition within six months, UK-based protein research tools supplier Abcam (AIM: ABC) has entered into a definitive agreement to buy Epitomics International, an antibody business headquartered in San Francisco, California, USA, with operations in China, for a gross consideration of $170.0 million. 6 March 2012
Pharmaceutical
As part of a series of strategic moves to build its laboratory information management system (LIMS) business in Europe and emerging markets in Latin America and Africa, STARLIMS Technologies, a subsidiary of US health care major Abbott (NYSE: ABT), has announced the acquisition of several longtime distribution partners. 4 March 2012
Pharmaceutical
UK pharma giant GlaxoSmithKline (LSE: GSK) says it has signed an agreement with Japan's third-largest drugmaker Daiichi Sankyo (TYO: 4568) to form a joint venture (JV) which is expected to create the number one vaccines company in Japan. Completion of the transaction is expected in the third quarter of this year, subject to local regulatory approvals. 2 March 2012
Pharmaceutical
Germany's Bayer (BAY: DE) is still confident that it can become a top-10 gobal pharmaceutical company, given its strong R&D pipeline with four potential blockbusters and also some acquisitions, the firm's chief executive, Marijn Dekkers, told journalists at the annual financial results conference in Leverkusen this week 1 March 2012
Pharmaceutical
Danish CNS drug specialist Lundbeck A/S (LUND: DC) and Germany's Paion AG (FSE: PA8) have entered into a definitive agreement under which Lundbeck acquires all of Paion's remaining rights to desmoteplase currently under clinical Phase III development for ischemic stroke. 29 February 2012
Pharmaceutical
Roche has extended its $5.7 billion hostile takeover offer for genetic sequencing specialist Illumina by a month, but has not chosen to increase its bid from the current level of $44.50 per share. 28 February 2012
Pharmaceutical
New Jersey, USA-based botanical therapeutics company Herborium (Pink Sheets: HBRM) says it has signed a Letter of Intent with China Health Resource (OTCBB CHRI) for the sale of up to a 100% interest in Herborium. 26 February 2012
Pharmaceutical
New upcoming treatments for Cushing's syndrome promise to improve patient's quality of life, according to a new report from pharmaceutical intelligence company GlobalData, which found that Cushing's syndrome patients can expect increasingly safe and effective pharmaceutical treatment options in the future, due to the expected launch of three late-stage pipeline molecules. 22 February 2012
Pharmaceutical
David Balto, an antitrust attorney in Washington DC, USA, and former Policy Director of the Federal Trade Commission, released a white paper yesterday exposing the flaws in efficiency claims made by US pharmacy benefit managers (PBMs) Express Scripts (Nasdaq: ESRX) and Medco Health Solutions (NYSE: MHS), with respect to their proposed merger. 20 February 2012
Pharmaceutical
Japan's Maruho says it has acquired Cutanea Life Sciences (CLS), a privately held dermatology development company based in Villanova, Pennsylvania, USA. CLS will become a wholly-owned subsidiary of Maruho. 15 February 2012
Pharmaceutical
Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Pharmaceutical
GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Pharmaceutical
Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze